Related news from
Fri, 31 Jul 2026 17:24:00 +0000	GMED's Q2 Earnings on Deck: Will Enabling Technologies Lead Results? Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.
Fri, 31 Jul 2026 15:30:23 +0000	Cencora (COR) Remains Attractive Despite Temporary Headwinds Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% and slightly outperforming the Russell Midcap® Value Index’s 13.40% gain. Information […]
Fri, 31 Jul 2026 13:15:02 +0000	Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Thu, 30 Jul 2026 21:25:01 +0000	Alignment Healthcare (ALHC) Beats Q2 Earnings and Revenue Estimates Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +30.77% and +1.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Thu, 30 Jul 2026 17:29:00 +0000	Charles River Prepares to Report Q2 Earnings: What's in Store? CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Thu, 30 Jul 2026 16:40:00 +0000	Revvity to Report Q2 Earnings: What's in Store for the Stock? RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?
Thu, 30 Jul 2026 14:00:15 +0000	Concentra Group (CON) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 29 Jul 2026 17:41:00 +0000	Good Neighbor Pharmacy® Named #1 in Customer Satisfaction with Chain Drug Store Pharmacies and Most Trusted by JD Power CONSHOHOCKEN, Pa., July 29, 2026--Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, has been ranked "#1 in Customer Satisfaction with Chain Drug Store Pharmacies" in the JD Power 2026 U.S. Pharmacy StudySM, a syndicated benchmarking study profiling the experiences of customers of the largest pharmacies in the United States. In addition to ranking highest overall, Good Neighbor Pharmacy ranked highest across four of seven dimensions: Pharmacy offerin
Wed, 29 Jul 2026 14:00:20 +0000	Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 29 Jul 2026 12:58:00 +0000	Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.
Tue, 28 Jul 2026 16:19:00 +0000	Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results? BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion pressure.
Tue, 28 Jul 2026 13:25:00 +0000	Henry Schein Prepares to Report Q2 Earnings: What's in the Cards? HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.
Mon, 27 Jul 2026 13:54:29 +0000	The Buyback Machine Hiding Behind Cardinal Health's Thin Margins A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.
Sat, 25 Jul 2026 22:11:58 +0000	Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace? Recent screening for stocks with rising P/E ratios and consistent price gains relative to the S&P 500 has put Cencora (COR) in focus for investors tracking valuation and earnings expectations. See our latest analysis for Cencora. Cencora’s recent screening attention comes after a generally mixed year for the share price, with a 30 day share price return of 8.94% contrasting with a year to date decline of 8.55% and a 1 year total shareholder return of 7.53%. This suggests longer term holders...
Sat, 25 Jul 2026 19:09:07 +0000	Cencora (COR) Stock Looks Undervalued As Its 167% Five Year Return Builds Cencora stock has delivered a strong 167.1% return over the past 5 years, yet its current valuation still screens as cheap. An intrinsic value estimate from a Discounted Cash Flow (DCF) model suggests the shares trade at a meaningful discount to that estimate, while market multiples also lean toward an undervalued verdict. A 167.1% total return over 5 years sets a high bar for Cencora. Any hint that cash flow growth slows or that returns on capital plateau may make the current valuation...
Fri, 24 Jul 2026 15:47:00 +0000	HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.
Fri, 24 Jul 2026 15:09:00 +0000	Here's Why You Should Add Cencora Stock to Your Portfolio Now COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Fri, 24 Jul 2026 12:04:00 +0000	Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.
Thu, 23 Jul 2026 18:07:00 +0000	MOH Q2 Earnings Beat on Lower Operating Expenses, 2026 EPS View Raised Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.
Thu, 23 Jul 2026 12:25:00 +0000	Bet on 5 Top-Ranked Stocks With Rising P/E Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!